Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by SeaBass91on Nov 30, 2018 11:55am
131 Views
Post# 29045613

RE:RE:New Year !!!

RE:RE:New Year !!!Well if you follow the News feeds and and what NASH is or is going to be doing, you can see that there is a Big Upside as it pertains to the Pharmaceutical sector.  I believe that this approach is going to pay off and move the sp above $1 or even $2 if you are willing to wait it out.... say 12 - 18 months.  Just MHO, however, the pharma sector is a big money sector and you only need One Winner to make it Pay Off in a significant way.  They have identified 13 candidates and whittled that down to 7 promising ones.....with NASH being their premiere choice....

Nothing is ever a Given and its always Speculative.... but if you can stand the heat in the kitchen then I think there are good payback on this one.... this one is not for day traders yet, but people with patience,

Cheers, glta  

Bullboard Posts